Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- NHI Price Revision in FY2017 and Annual NHI Price Revision Should Be Discussed Separately: Shirakawa
June 11, 2015
- Chuikyo Begins Discussions on FY2016 NHI Pricing Reform; Drug Pricing Organization to Present Views at Next Meeting
June 11, 2015
- PAFSC Second Committee to Discuss Olanexidine, Zosyn on June 17
June 10, 2015
- LDP Eyes Filing of 15 Sakigake Designated Products by FY2018
June 9, 2015
- Kaketsuken Suspends Shipments of 12 Products Due to Modifications of Approved Manufacturing Procedures
June 9, 2015
- Editor’s Pick: Five Healthcare News Headlines for May 25 - June 7
June 8, 2015
- MHLW’s Jo Urges Generic Makers to Formulate Careful Investment Plans
June 8, 2015
- Govt Working Group Suspicious about Supply Limitation Hindering Generic Goal
June 8, 2015
- PAFSC 1st Committee Backs Approval of Lilly’s GLP-1 Receptor Agonist Dulaglutide
June 8, 2015
- 8 Members of PAFSC’s Pharmaceutical Affairs Council to Be Ousted for Violating COI Rules
June 8, 2015
- Roughly 60 Products Submitted as Candidates for Review under Sakigake Designation System
June 8, 2015
- LDP Study Group Agrees on Good Balance between Generic Promotion, Innovation
June 5, 2015
- Prime Minister Abe Asks Health Minister to Formulate New Measures against Cancer by Year-End
June 4, 2015
- MHLW to Launch Switch OTC Panel as Early as Summer
June 3, 2015
- MHLW Calls for Revision of Package Insert for Xalkori
June 3, 2015
- MHLW Stands by “80% in FY2020” as New Generic Use Target, Says It’s “Barely Reachable”
June 2, 2015
- MOF Panel Recommends Generic Target of 80% by FY2017-End
June 2, 2015
- JPMA Says Generic Target Has Huge Impact on Innovation, Balanced Approach Needed
June 1, 2015
- Lawmakers Tepid on Health Issues amid Weak Lobbying Campaigns on Generics, Drug Price Cuts
June 1, 2015
- AMED Hopes to Create Fund to Nurture Researchers through Contributions from Drug Makers: President Suematsu
June 1, 2015
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…